(NASDAQ: MRKR) Marker Therapeutics's forecast annual revenue growth rate of 257.99% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.48%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.37%.
Marker Therapeutics's revenue in 2025 is $6,591,080.On average, 1 Wall Street analysts forecast MRKR's revenue for 2027 to be $246,307,115, with the lowest MRKR revenue forecast at $246,307,115, and the highest MRKR revenue forecast at $246,307,115. On average, 1 Wall Street analysts forecast MRKR's revenue for 2028 to be $1,565,656,531, with the lowest MRKR revenue forecast at $1,565,656,531, and the highest MRKR revenue forecast at $1,565,656,531.
In 2029, MRKR is forecast to generate $3,309,082,545 in revenue, with the lowest revenue forecast at $3,309,082,545 and the highest revenue forecast at $3,309,082,545.